港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

生物医药B类股

801.832

-11.254-1.38%

涨家数：10

跌家数：23

平家数：1

市盈率：- -

高：825.541

开：813.411

低：798.667

收：813.086

成交量：1.40亿

成交额：38.54亿

市值：4,808.06亿

流通市值：4,368.88亿

数据加载中...

信立泰股价微涨0.66% 化学制药企业研发管线引关注

歌礼制药-B(01672)8月25日发行2882万股

新股消息 | 劲方医药通过港交所聆讯报告期内持续亏损

先瑞达医疗-B(06669)：外周可控机械解脱带纤维毛弹簧圈的注册申请获中国国家药品监督管理局批准

先瑞达医疗-B获得中国国家药监局批准其外周可控机械分离纤维弹簧圈产品

据港交所文件：劲方医药科技股份有限公司 - B通过港交所上市聆讯。

据港交所文件：劲方医药科技（上海）股份有限公司 - B通过港交所上市聆讯。

富国基金赵伟：创新药行情才刚刚开始下一个10倍股可能来自自免和代谢领域

归创通桥(02190)8月25日斥资118.42万港元回购5万股

腾盛博药-B(02137)因受限制股份单位获归属而发行13.08万股

集采倒逼传统药企转型，多家企业创新药收入贡献过半

恒瑞医药(01276.HK)：HRS-2162注射液获药物临床试验批准通知书

研报掘金丨平安证券：维持鱼跃医疗“强烈推荐”评级，看好公司持续增长能力

药师帮五年跃迁：从“送炭者”到“造风者” ——解码数字化重构医药供应链，半年净利激增3倍之迷｜我们这五年

交银国际：升先声药业(02096.HK)目标价至16.4港元维持“买入”评级

港股异动 | 北海康成-B(01228)再涨超12% 公司获百洋医药战略投资旗下三款产品通过商保创新药目录初审

研报掘金丨华西证券：维持丸美生物“买入”评级，品牌聚焦大单品战略持续发力

大行评级｜招商证券国际：上调中国生物制药目标价至9.8港元指其潜力被低估

健康元半年报解读：PDE4等创新药构建顶级呼吸壁垒下半年或迎戴维斯双击

康方生物公布三期临床试验积极结果：古莫替尼单抗治疗强直性脊柱炎和曼菲多昔单抗治疗特应性皮炎均达到主要终点

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1574/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":801.832,"timestamp":1756187015793,"preClose":813.08563,"halted":0,"volume":139908145,"delay":0,"changeRate":-0.013841,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-11.253662,"latestTime":"08-26 13:43:35","open":813.4112,"high":825.54065,"low":798.6673,"amount":3854299651,"amplitude":0.033051,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1756195800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1756171800000,1756180800000],[1756184400000,1756195200000]],"pbRate":6.722096,"peRate":-40.784235,"turnoverRate":0.005233,"increases":10,"decrements":23,"flats":0,"marketCap":480805867392,"floatMarketCap":436888096160},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":825.54065,"amplitude":0.033051,"preClose":813.08563,"low":798.6673,"pbRate":"6.722096","latestPrice":801.832,"volume":139908145,"delay":0,"open":813.4112,"prevYearClose":331.1933,"prevWeekClose":829.54,"prevMonthClose":735.033,"prevQuarterClose":555.617,"fiveDayClose":830.772,"twentyDayClose":768.836,"sixtyDayClose":474.737,"secType":"PLATE","market":"HK","turnoverRate":0.005233,"peRate":-40.784235,"marketCap":480805867392,"floatMarketCap":436888096160,"timestamp":1756187015793,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":10,"down":23,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2562226791","title":"信立泰股价微涨0.66% 化学制药企业研发管线引关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2562226791","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562226791?lang=zh_cn&edition=fundamental","pubTime":"2025-08-26 00:31","pubTimestamp":1756139514,"startTime":"0","endTime":"0","summary":"信立泰最新股价报53.09元，较前一交易日上涨0.35元。盘中最高触及54.40元，最低下探52.11元，全天成交金额达5.04亿元，换手率为0.85%。该公司主营业务为化学制药，专注于心血管、抗感染、抗肿瘤等领域的创新药物研发。作为深圳特区企业，信立泰已建立起从原料药到制剂的全产业链布局，拥有多项核心专利技术。从资金流向来看，8月25日主力资金净流出5214.05万元，近五个交易日累计净流出8836.77万元。当前公司总市值591.86亿元，市盈率为81.06倍。风险提示：股市有风险，投资需谨慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/26003152679708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0196","BK0187","BK1574","BK1191","BK0239","BK0028","002294","01477","BK0188","BK0183"],"gpt_icon":0},{"id":"2562264247","title":"歌礼制药-B(01672)8月25日发行2882万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2562264247","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562264247?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 21:44","pubTimestamp":1756129453,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2025年8月25日根据日期为2025年8月19日的配售及认购协议, 根据一般授权配发及发行2882万股新股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01672","BK1574","BK1161","01477","BK1515"],"gpt_icon":0},{"id":"2562426002","title":"新股消息 | 劲方医药通过港交所聆讯 报告期内持续亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=2562426002","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562426002?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 21:14","pubTimestamp":1756127690,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所8月25日披露，劲方医药科技(上海)股份有限公司通过港交所上市聆讯，中信证券为其独家保荐人。公司已在中国启动针对携带KRAS G12D突变的晚期实体瘤患者的I/II期临床试验的II期部分。KRAS G12D是最常见的致癌基因KRAS突变，尚无获批的治疗方案可用。财务方面，于2023年度、2024年度及2025年截至4月30日止四个月，劲方医药现收入分别约为7373.4万元、1.05亿元、8214.9万元人民币；年/期内亏损分别约为5.08亿元、6.78亿元、6662.4万元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334778.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1515","09939","HEXmain","BK1574","BK1161"],"gpt_icon":0},{"id":"2562564242","title":"先瑞达医疗-B(06669)：外周可控机械解脱带纤维毛弹簧圈的注册申请获中国国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2562564242","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562564242?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 21:12","pubTimestamp":1756127538,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先瑞达医疗-B(06669)发布公告，于2025年8月22日，集团收到中国国家药品监督管理局对外周可控机械解脱带纤维毛弹簧圈的注册批准。本产品用于外周血管的动脉瘤、动静脉畸形和动静脉瘘的填塞。本产品采用可控解脱机制，确保弹簧圈释放过程稳定、精准，提升了操作的可控性和安全性。此外，产品具有2D和3D两种结构可选择，能够广泛适配临床需求。公司将适时在中国开展营销活动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334784.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","BK1587","BK1574","06669"],"gpt_icon":0},{"id":"1172020994","title":"先瑞达医疗-B获得中国国家药监局批准其外周可控机械分离纤维弹簧圈产品","url":"https://stock-news.laohu8.com/highlight/detail?id=1172020994","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172020994?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 21:01","pubTimestamp":1756126890,"startTime":"0","endTime":"0","summary":"先瑞达医疗-B宣布，公司的外周可控机械分离纤维弹簧圈产品已获得中国国家药品监督管理局的正式批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1100","BK1587","06669"],"gpt_icon":0},{"id":"2562241464","title":"据港交所文件：劲方医药科技股份有限公司 - B通过港交所上市聆讯。","url":"https://stock-news.laohu8.com/highlight/detail?id=2562241464","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562241464?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 20:27","pubTimestamp":1756124848,"startTime":"0","endTime":"0","summary":"据港交所文件：劲方医药科技股份有限公司 - B通过港交所上市聆讯。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/25202752675572.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","159938","BK1161","BK1515","09939"],"gpt_icon":0},{"id":"2562524166","title":"据港交所文件：劲方医药科技（上海）股份有限公司 - B通过港交所上市聆讯。","url":"https://stock-news.laohu8.com/highlight/detail?id=2562524166","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562524166?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 20:22","pubTimestamp":1756124521,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","BK1515","BK1161","159938","BK1574","HEXmain"],"gpt_icon":0},{"id":"2562524658","title":"富国基金赵伟：创新药行情才刚刚开始 下一个10倍股可能来自自免和代谢领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2562524658","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562524658?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 19:27","pubTimestamp":1756121233,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，富国基金基金经理赵伟分享了对医药市场尤其对创新药的看法。赵伟指出，创新药现在是起点，刚刚开始。他认为自免和代谢领域机会很大。从今年、明年开始，国内获批新药的数量还会持续增长，未来中国创新药的获批量很可能会迎来井喷。此外，这轮创新药行情的最核心逻辑是出海。肿瘤是美国和中国最大的治疗领域。赵伟表示，未来投资要看胜率和赔率，真正的大单品可能是下一个十倍股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334661.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","159992","06978"],"gpt_icon":0},{"id":"2562434462","title":"归创通桥(02190)8月25日斥资118.42万港元回购5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2562434462","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562434462?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 18:50","pubTimestamp":1756119031,"startTime":"0","endTime":"0","summary":"智通财经APP讯，归创通桥(02190)发布公告，于2025年8月25日，该公司斥资118.42万港元回购5万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334606.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02190","BK1574","BK1583","BK1100","BK1587"],"gpt_icon":0},{"id":"2562724892","title":"腾盛博药-B(02137)因受限制股份单位获归属而发行13.08万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2562724892","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562724892?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 18:23","pubTimestamp":1756117393,"startTime":"0","endTime":"0","summary":"智通财经APP讯，腾盛博药-B(02137)发布公告，于2025年8月25日，该公司根据于2021年6月22日采纳的公司首次公开发售后股份奖励计划，归属授出的受限制股份单位而发行及配发予公司雇员的13.08万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","02137","BK1587"],"gpt_icon":0},{"id":"2562439652","title":"集采倒逼传统药企转型，多家企业创新药收入贡献过半","url":"https://stock-news.laohu8.com/highlight/detail?id=2562439652","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562439652?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 18:14","pubTimestamp":1756116894,"startTime":"0","endTime":"0","summary":"2018年药品集采政策推行后，很多依赖仿制药收入的传统药企，利润在一夜之间锐减。面对这种形势，企业们纷纷吹响向创新药企转型号角。现如今，药企的转型初见成效。近日，多家药企公布的2025年半年报显示，创新药已撑起了公司一半以上的收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202508253493664948.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202508253493664948.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2562175242","title":"恒瑞医药(01276.HK)：HRS-2162注射液获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2562175242","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562175242?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 17:29","pubTimestamp":1756114197,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1328615791.USD","159938","BK1191","LU2543165471.USD","LU1997245094.SGD","BK0196","LU1997245177.USD","600276","BK0183","LU0359201885.HKD","01276","LU0405327148.USD","LU0405327494.USD","BK0188","BK1574","LU1064130708.USD","LU2488822045.USD","BK0239","LU1064131003.USD","LU0359201612.USD","BK1161","LU1255011170.USD","LU2328871848.SGD","09939","LU2495084118.USD","BK0028","BK1515","LU2148510915.USD","BK0012","BK0060","LU1655091616.SGD","LU1997244956.HKD","LU1023057109.AUD","LU0359202008.SGD","LU1969619763.USD","LU2580892789.USD","LU2580892862.HKD"],"gpt_icon":0},{"id":"2562521293","title":"研报掘金丨平安证券：维持鱼跃医疗“强烈推荐”评级，看好公司持续增长能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2562521293","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562521293?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 17:17","pubTimestamp":1756113448,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0188","BK0114","09997","BK0185","161027","BK1574","BK1222","159883","BK1100","09996","002223","BK0146","BK0197","BK0251","BK1583","BK0070"],"gpt_icon":0},{"id":"2562126692","title":"药师帮五年跃迁：从“送炭者”到“造风者” ——解码数字化重构医药供应链，半年净利激增3倍之迷｜我们这五年","url":"https://stock-news.laohu8.com/highlight/detail?id=2562126692","media":"华夏时报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562126692?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 17:06","pubTimestamp":1756112782,"startTime":"0","endTime":"0","summary":"扎根基层市场，以数字化为杠杆撬动产业链，药师帮在医药产业数字化变革浪潮中持续耕耘，终在2025年结出硕果。2025年8月20日，药师帮（09885.HK）发布2025年半年报，公司上半年营业收入达到98.43亿元，同比增长11.7%；归母净利润达到7800万元，同比激增3倍以上，延续2024年首次实现全年盈利的强劲势头。回溯过去的五年，医药行业经历了深刻的变革。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202508253493610579.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202508253493610579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1197","09939","BK1574","BK1161","09885","BK1515"],"gpt_icon":0},{"id":"2562921193","title":"交银国际：升先声药业(02096.HK)目标价至16.4港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2562921193","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562921193?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 16:12","pubTimestamp":1756109566,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","02096","BK1191","BK1583","159992","06978","BK1161"],"gpt_icon":0},{"id":"2562216883","title":"港股异动 | 北海康成-B(01228)再涨超12% 公司获百洋医药战略投资 旗下三款产品通过商保创新药目录初审","url":"https://stock-news.laohu8.com/highlight/detail?id=2562216883","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562216883?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 15:19","pubTimestamp":1756106359,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，北海康成-B再涨超12%，年内累计涨幅已接近20倍。消息面上，8月13日，北海康成宣布与百洋医药达成股份认购协议，根据协议，百洋医药将斥资1亿港元认购北海康成股份。与此同时，北海康成与百洋医药双方通过签订独家商业化服务协议，进一步深化战略协同。此外，2025年，国家医保局首次设立“商保创新药目录”，并于7月11日正式启动申报工作。市场人士称，通过初审名单，对于北海康成意义重大。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01228","BK1574","159992","06978","BK1161","BK0250","301015"],"gpt_icon":0},{"id":"2562521329","title":"研报掘金丨华西证券：维持丸美生物“买入”评级，品牌聚焦大单品战略持续发力","url":"https://stock-news.laohu8.com/highlight/detail?id=2562521329","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562521329?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 14:42","pubTimestamp":1756104143,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1583","BK1222","BK1574","09996","BK1100","603983","159883","BK0229","PL","09997","002926","BK0276","159837","BK4123"],"gpt_icon":0},{"id":"2562821338","title":"大行评级｜招商证券国际：上调中国生物制药目标价至9.8港元 指其潜力被低估","url":"https://stock-news.laohu8.com/highlight/detail?id=2562821338","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562821338?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 14:21","pubTimestamp":1756102903,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["01477","BK1147","BK1574","BK1191","IE00BZ08YT58.USD","01177","IE00BZ08YS42.EUR","BK1589","BK1515","06099","IE00BZ08YR35.GBP","BK1564","BK1521"],"gpt_icon":0},{"id":"2562216831","title":"健康元半年报解读：PDE4等创新药构建顶级呼吸壁垒 下半年或迎戴维斯双击","url":"https://stock-news.laohu8.com/highlight/detail?id=2562216831","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562216831?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 14:05","pubTimestamp":1756101900,"startTime":"0","endTime":"0","summary":"8月22日晚，健康元发布2025年半年报。在医药行业政策推动与竞争压力并存的背景下，公司用一份“半年报答卷”释放了个关键信号：创新药价值逐渐兑现的前奏。　　呼吸疾病是全球常见慢病之一，COPD是全球第三大死亡原因，哮喘患者超三亿。健康元重点布局呼吸创新药十几年，已进入业绩兑现周期，研发能力获证明。今年7月默沙东收购Verona Pharma，提升呼吸创新药企估值，健康元有望业绩、估值双提升，符合戴维斯双击样本。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2025-08-25/doc-infnesif9135936.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0046","BK1574","159992","BK0239","600380","06978","BK1161","BK0077","BK0114","BK0188"],"gpt_icon":0},{"id":"1148749910","title":"康方生物公布三期临床试验积极结果：古莫替尼单抗治疗强直性脊柱炎和曼菲多昔单抗治疗特应性皮炎均达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1148749910","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148749910?lang=zh_cn&edition=fundamental","pubTime":"2025-08-25 13:47","pubTimestamp":1756100834,"startTime":"0","endTime":"0","summary":"康方生物公布三期临床试验积极结果：古莫替尼单抗治疗强直性脊柱炎和曼菲多昔单抗治疗特应性皮炎均达到主要终点","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720050803.USD","09926","BK1574","IE00BPRC5H50.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU0417516571.SGD","BK1161","LU0348784397.USD","LU0348783233.USD","LU2488822045.USD","LU1794554557.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":23,"pageCount":2,"totalSize":446,"code":"91000000","status":"200"}]}}